Results 261 to 270 of about 6,208,817 (342)

Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Andreas Meier   +8 more
wiley   +1 more source

Reconstitution of CXCR3+ CCR6+ Th17.1‐Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Objectives Ofatumumab, a fully human anti‐CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing–remitting multiple ...
Shu Yang   +9 more
wiley   +1 more source

Incidence of Side Effects Associated With Acetaminophen in People Aged 65 Years or More: A Prospective Cohort Study Using Data From the Clinical Practice Research Datalink

open access: yesArthritis Care &Research, EarlyView.
Objective The main objective of this study is to examine the safety of oral acetaminophen at its therapeutic dose in adults aged ≥65 years. Methods This population‐based cohort study used the Clinical Practice Research Datalink‐Gold data. Participants were aged ≥65 years registered with a UK general practice for at least 12 months between 1998 and 2018.
Jaspreet Kaur   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy